Nanne K.H. de Boer - Concepedia

Author

Nanne K.H. de Boer

Amsterdam UMC Location Vrije Universiteit Amsterdam ORCID

Also Known As

Boer, Nanne K. De, Boér K, Cyriel Y. Ponsioen, De Boer, N. K.H., K BOER, K Boér, K H N de Boer, K. Boer, K. Böer, N DEBOER

519

Publications

9.4K

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location Vrije Universiteit Amsterdam Vrije Universiteit Amsterdam Amsterdam University Medical Centers Radboud University Nijmegen Radboud University Medical Center

About

Nanne K.H. de Boer is an author at Amsterdam UMC Location Vrije Universiteit Amsterdam specializing in medicine, gastroenterology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	27	1.9K
2	Public Health	3	3	165
3	Education	1	1	15
4	Engineering	1	1	160
5	Health Sciences	1	1	13

Nanne K.H. de Boer

147

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial Cyriel Y. Ponsioen, E. Joline de Groof, Emma J. Eshuis, The Lancet. Gastroenterology & hepatology Terminal IleitisGastroenterologyMulticentre TrialSurgeryClinical Gastroenterology	2017	334
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Bruce E. Sands, Peter M. Irving, Timothy Hoops, The Lancet ImmunologyClinical TrialsGastroenterologyMaintenance TherapyBiological Therapy	2022	277
Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts Bindia Jharap, Margien L. Seinen, Nanne K.H. de Boer, Inflammatory Bowel Diseases	2010	197
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study Vince Biemans, Andrea E. van der Meulen‐de Jong, C. Janneke van der Woude, Journal of Crohn s and Colitis	2019	176
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial Toer Stevens, Maria L. Haasnoot, Geert D’Haens, The Lancet. Gastroenterology & hepatology Terminal IleitisMedicineC TrialGastroenterologyClinical Gastroenterology	2020	173
Azathioprine Use During Pregnancy: Unexpected Intrauterine Exposure to Metabolites Nanne K.H. de Boer, Soeresh V A Jarbandhan, Peer de Graaf, The American Journal of Gastroenterology	2006	163
Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study Tim G. de Meij, Ilhame Ben Larbi, Marc P. van der Schee, International Journal of Cancer EngineeringPrinciple StudyGastroenterologyPathologyColorectal Carcinoma	2013	160
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis Eduard Cornelis Verschuren, A.J. van den Eertwegh, Janneke Wonders, Clinical Gastroenterology and Hepatology GastroenterologyPathologyGi TechniqueClinical GastroenterologyGastrointestinal Pathology	2015	142
Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease Bindia Jharap, Nanne K.H. de Boer, Pieter Stokkers, Gut	2013	140
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment Vince Biemans, C. Janneke van der Woude, Gerard Dijkstra, Alimentary Pharmacology & Therapeutics	2020	123

Page 1